Table 1.

Patient characteristics of the 95 patients from the EURTAC trial included in the present study

Total (N = 95) N (%)Erlotinib (N = 50) N (%)Chemotherapy (N = 45) N (%)P
Gender0.1112a
 Female71 (74.74)34 (68.00)37 (82.22)
 Male24 (25.26)16 (32.00)8 (17.78)
Age0.9481a
 <65 y44 (46.32)23 (46.00)21 (46.67)
 ≥65 y51 (53.68)27 (54.00)24 (53.33)
Smoking history0.3120b
 Never smoked64 (67.37)32 (64.00)32 (71.11)
 Former smoker23 (24.21)15 (30.00)8 (17.78)
 Current smoker8 (8.42)3 (6.00)5 (11.11)
ECOG performance status0.7263a
 031 (32.63)15 (30.00)16 (35.56)
 151 (53.68)27 (54.00)24 (53.33)
 213 (13.68)8 (16.00)5 (11.11)
Histology0.0193b
 Adenocarcinoma87 (91.58)47 (94.00)40 (88.89)
 Bronchioalveolar adenocarcinoma1 (1.05)0 (0.00)1 (2.22)
 Large cell carcinoma2 (2.11)2 (4.00)0 (0.00)
 Squamous cell carcinoma1 (1.05)1 (2.00)0 (0.00)
 Other4 (4.21)0 (0.00)4 (8.89)
Tumor stage0.4381b
 IIIB (malignant effusion)7 (7.37)5 (10.00)2 (4.44)
 IV87 (91.58)44 (88.00)43 (95.56)
 Unknownc1 (1.05)1 (2.00)0 (0.00)
Lung or pleura metastasis0.6017b
 Yes92 (96.84)49 (98.00)43 (95.56)
 No3 (3.16)1 (2.00)2 (4.44)
Bone metastasis0.3139a
 Yes27 (28.42)12 (24.00)15 (33.33)
 No68 (71.58)38 (76.00)30 (66.67)
Brain metastasis0.2505a
 Yes11 (11.58)4 (8.00)7 (15.56)
 No84 (88.42)46 (92.00)38 (84.44)
Type of EGFR mutation0.7643a
 del 1964 (67.37)33 (66.00)31 (68.89)
 L858R31 (32.63)17 (34.00)14 (31.11)
T790M mutation0.5548a
 Detected62 (65.26)34 (68.00)28 (62.22)
 Not detected33 (34.74)16 (32.00)17 (37.78)
TP53 mutations0.5950a
 Detected23 (24.21)10 (20.00)13 (28.89)
 Not detected59 (62.11)33 (66.00)26 (57.78)
 No datad13 (13.68)7 (14.00)6 (13.33)
BIM expression0.5418a
 Low/intermediate53 (55.79)26 (52.00)27 (60.00)
 High30 (31.58)16 (32.00)14 (31.11)
 No datad12 (12.63)8 (16.00)4 (8.89)
Response<0.0001b
 Complete response1 (1.05)1 (2.00)0 (0.00)
 Partial response32 (33.68)27 (54.00)5 (11.11)
 Stable disease34 (35.79)12 (24.00)22 (48.89)
 Progressive disease14 (14.74)6 (12.00)8 (17.78)
 Unknownc14 (14.74)4 (8.00)10 (22.22)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aχ2 test.

  • bFisher test.

  • cInformation not recorded (percentages are based on all 95 patients).

  • dInsufficient tumor tissue for analysis (percentages are based on all 95 patients).